CELU News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CE

Mkt Cap

$40.7M

Volume

62.85K

Next Earnings

November 13th

Loading chart

CE

CELUCelularity Inc. Class A Common Stock

CELU

Pay with—

Available Balance0.00

CE

Mkt Cap

$40.6M

Volume

62.85K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

Celularity Provides Update Regarding Nasdaq Listing ComplianceCelularity Inc. (Nasdaq: CELU) received a notification from Nasdaq on August 21, 2026, stating the company is not in compliance with listing rules due to failure to timely file its Quarterly Reports on Form 10-Q for periods ended June 30, 2026 and March 31, 2026. The company has until September 4, 2026 to submit a compliance plan, with a maximum 180-day grace period until November 16, 2026. Trading of the stock continues unaffected while the company works to complete and file the delayed reports.GlobeNewswire Inc. · Aug 25, 2026

Celularity Receives Nasdaq Notice Regarding Form 10-QCelularity Inc. received a notification from Nasdaq on May 27, 2026, indicating non-compliance with Listing Rule 5250(c)(1) due to delayed filing of its Quarterly Report on Form 10-Q for Q1 2026. The company has until July 28, 2026, to submit a compliance plan, with a potential extension until November 16, 2026. Trading of the stock continues unaffected, and the company is working to file the report and regain compliance.GlobeNewswire Inc. · May 29, 2026

EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple RevenueNexGel (NASDAQ: NXGL) agreed to acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity (NASDAQ: CELU). The transaction is expected to nearly triple NexGel's annual revenue to approximately $35 million in 2026 and make the company immediately profitable. The portfolio includes six commercial-stage products focused on tendon repair, skin grafts, and bone growth with over a decade of clinical use and existing insurance reimbursement pathways.Benzinga · Mar 10, 2026

Celularity Receives Nasdaq Notice Regarding Form 10-QCelularity received a Nasdaq notification for not timely filing its Quarterly Report on Form 10-Q for June 30, 2025, potentially risking its listing compliance, with a deadline of September 5, 2025 to submit a compliance plan.GlobeNewswire Inc. · Aug 22, 2025

Celularity Receives Nasdaq Notice Regarding Form 10-QCelularity Inc. (CELU) announced that it did not timely file its Q1 2025 financial report, leading to a Nasdaq non-compliance notice. The company has 60 days to submit a plan to regain compliance and may be granted an extension until November 2025 if the plan is accepted.GlobeNewswire Inc. · May 30, 2025

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq FeesCelularity Inc. (CELU) received a Nasdaq delisting notice due to unpaid fees and a delinquent SEC filing. The company paid the outstanding fees and is working to file the 2024 Form 10-K.GlobeNewswire Inc. · Apr 25, 2025

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes ProductsCelularity welcomes CMS action to delay the effective date of a Medicare LCD for skin substitute products used to treat diabetic foot ulcers and venous leg ulcers from February 2025 to January 2026, ensuring continued access to these critical wound care products for Medicare patients.GlobeNewswire Inc. · Apr 14, 2025

Amniotic Products Global Industry Report 2025: Growth in Regenerative Medicine Propels the Use of Amniotic Products in Tissue Repair and HealingThe global amniotic products market is expected to grow significantly, driven by advancements in regenerative medicine and the increasing use of amniotic products in tissue repair and healing. The Amniotic Membranes segment is projected to reach $1.2 billion by 2030, while the Amniotic Suspensions segment is also set to grow at a CAGR of 6.6%.GlobeNewswire Inc. · Jan 3, 2025

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance MatterCelularity Inc. has regained compliance with Nasdaq listing rules after addressing a backlog of financial filings. The company has implemented process improvements, including engaging a new audit firm, to ensure timely and accurate reporting going forward.GlobeNewswire Inc. · Dec 10, 2024

Celularity Inc. Announces Receipt of Nasdaq NotificationCelularity Inc. received a notification from Nasdaq stating that the company does not comply with the Nasdaq continued listing requirements due to its inability to timely file its Q3 2024 Form 10-Q. The company plans to submit a plan to regain compliance by January 20, 2025, but there is no assurance that Nasdaq will accept the plan or that the company will regain compliance within the compliance period.GlobeNewswire Inc. · Nov 27, 2024

to start trading

CE

CELUCelularity Inc. Class A Common Stock

CELU

Pay with—

Available Balance0.00

Your PositionYou don't own any CELU yet.

Related Tickers

Earnings